Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Change in Cash (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Change in Cash data on record, last reported at $2.1 million in Q3 2025.

  • For Q3 2025, Change in Cash rose 143.26% year-over-year to $2.1 million; the TTM value through Sep 2025 reached -$3.2 million, down 141.65%, while the annual FY2024 figure was -$1.4 million, 131.46% down from the prior year.
  • Change in Cash reached $2.1 million in Q3 2025 per GANX's latest filing, up from -$2.4 million in the prior quarter.
  • Across five years, Change in Cash topped out at $39.1 million in Q1 2021 and bottomed at -$20.0 million in Q2 2022.
  • Average Change in Cash over 5 years is $70483.6, with a median of -$2.0 million recorded in 2023.
  • The widest YoY moves for Change in Cash: up 6097.57% in 2021, down 695.26% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$4.1 million in 2021, then rose by 13.07% to -$3.6 million in 2022, then skyrocketed by 311.01% to $7.5 million in 2023, then crashed by 122.14% to -$1.7 million in 2024, then skyrocketed by 226.85% to $2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $2.1 million in Q3 2025, -$2.4 million in Q2 2025, and -$1.3 million in Q1 2025.